ea0046oc3 | (1) | UKINETS2016
Horsch D
, Kulke M
, Caplin M
, Anthony L
, Bergsland E
, Oberg K
, Welin S
, Warner R
, Lombard-Bohas C
, Kunz P
, Valle J
, Fleming D
, Lapuerta P
, Banks P
, Pavel M
Introduction: TELESTAR was a pivotal, randomized phase 3 study evaluating telotristat etiprate (TE), a tryptophan hydroxylase inhibitor, among patients (pts) with carcinoid syndrome (CS). When added to somatostatin analogues (SSA), 250 mg tid and 500 mg tid TE each produced significantly greater bowel movement (BM) frequency reduction averaged over 12 weeks (wks) than placebo (PBO) plus SSA (P<0.001). Pts crossed over to open-label (OL) treatment with TE 500 mg ti...